Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
J Autoimmun ; 33(2): 147-54, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19447008

ABSTRACT

B-cells influence T-cell reactivity by facilitating antigen presentation, but the role of autoantibody-secreting B-cells in regulating T-cell responses in Type 1 diabetes is poorly defined. The aims of this study were to characterise epitopes on the IA-2 autoantigen for three monoclonal antibodies from diabetic patients by amino acid substitutions of selected residues of IA-2, establish contributions of these epitopes to binding of serum antibodies in Type 1 diabetes and relate B- and T-cell responses to overlapping determinants on IA-2. The monoclonal antibodies recognised overlapping epitopes, with residues within the 831-860 region of IA-2 contributing to binding; substitution of Glu836 inhibited binding of all three antibodies. Monoclonal antibody Fab fragments and substitution of residues within the 831-836 region blocked serum antibody binding to an IA-2 643-937 construct. IL-10-secreting T-cells responding to peptides within the 831-860 region were detected by cytokine-specific ELISPOT in diabetic patients and responses to 841-860 peptide were associated with antibodies to the region of IA-2 recognised by the monoclonal antibodies. The study identifies a region of IA-2 frequently recognised by antibodies in Type 1 diabetes and demonstrates that these responses are associated with T-cells secreting IL-10 in response to a neighbouring determinant.


Subject(s)
Autoantibodies/immunology , Autoantigens/immunology , Diabetes Mellitus, Type 1/immunology , Epitopes, T-Lymphocyte/immunology , Receptor-Like Protein Tyrosine Phosphatases, Class 8/immunology , T-Lymphocytes/immunology , Adolescent , Adult , Amino Acid Substitution , Antibodies, Monoclonal/immunology , Child , Epitopes, T-Lymphocyte/genetics , Female , Humans , Infant , Interferon-gamma/biosynthesis , Interferon-gamma/immunology , Interleukin-10/biosynthesis , Interleukin-10/immunology , Male , Receptor-Like Protein Tyrosine Phosphatases, Class 8/genetics , T-Lymphocytes/metabolism , Young Adult
3.
Clin Exp Immunol ; 121(1): 100-5, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10886245

ABSTRACT

Type 1 diabetes is a T cell-mediated autoimmune disease where a number of islet beta-cell target autoantigens have been characterized on the basis of reactivity with autoantibodies. Nevertheless, there remains uncertainty of the nature of another group of autoantigens associated with the secretory granule fraction of islet beta-cells that appear to be targeted predominantly by autoreactive T cells. We have previously characterized CD4+, HLA-DR-restricted T cell lines from new onset type 1 diabetic patients that are specific for the secretory granule fraction of rat tumour insulinoma, RIN. The T cell line from the first patient, HS, proliferates in response to crude microsomal membranes prepared from a recently established, pure human islet beta-cell line NES2Y. In addition, the HS line also responds to secretory granule fractions prepared from a murine tumour insulinoma grown in RIP-Tag mice, showing the recognition of species-conserved antigen(s) in beta-cells. Using partially matched antigen-presenting cells, the HS T cells and another line derived from a second patient, MR, were shown to be restricted by disease-associated DRB1*0101 and DRB1*0404 alleles, respectively. Neither the HS or MR T cell lines proliferate in response to a large panel of candidate islet cell antigens, including insulin, proinsulin, glutamic acid decarboxylase, the protein tyrosine phosphatase IA-2/phogrin, imogen-38, ICA69 or hsp60. Our data provide compelling evidence of the presence of a group of antigens associated with the secretory granule fraction of islet beta-cells recognized by the T cell lines, whose definition may contribute to our knowledge of disease induction as well as to diagnosis.


Subject(s)
Diabetes Mellitus, Type 1/immunology , Islets of Langerhans/immunology , T-Lymphocytes/immunology , Animals , Cells, Cultured , Cytoplasmic Granules , Humans , Islets of Langerhans/cytology , Mice , Rats , Rats, Wistar , Tumor Cells, Cultured
4.
Clin Endocrinol (Oxf) ; 52(6): 789-93, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10848885

ABSTRACT

We present a case of Cushing's syndrome where 111In-octreotide scanning provided evidence for the presence of two neuroendocrine tumours. Uptake in the right neck corresponded to a chemodectoma, but there was no change in the clinical condition or fall in ACTH levels following surgical resection. Uptake in the left chest was assumed to relate to a bronchial carcinoid, but a tumour could not initially be localized on magnetic resonance imaging (MRI), spiral CT scanning or on selective venous sampling. A 1 cm bronchial carcinoid tumour was identified post-mortem which immunostained for ACTH. This case demonstrates that 111ln-octreotide scanning is a useful technique for identifying the source of ectopic ACTH production in difficult cases of Cushing's syndrome. Reliance should not be placed solely on standard imaging techniques to localize the tumour prior to surgery. Although rare, the possibility of a non-ACTH secreting neuroendocrine tumour should also be considered in patients with ectopic ACTH syndrome, who have positive 111In-octreotide scans.


Subject(s)
Bronchial Neoplasms/complications , Carcinoid Tumor/complications , Cushing Syndrome/etiology , Neoplasms, Multiple Primary/complications , Paraganglioma, Extra-Adrenal/complications , Adult , Angiography, Digital Subtraction , Bronchial Neoplasms/diagnostic imaging , Bronchial Neoplasms/pathology , Carcinoid Tumor/diagnostic imaging , Carcinoid Tumor/pathology , Carotid Arteries , Cushing Syndrome/diagnostic imaging , Cushing Syndrome/pathology , Humans , Indium Radioisotopes , Male , Neoplasms, Multiple Primary/diagnostic imaging , Neoplasms, Multiple Primary/pathology , Octreotide , Paraganglioma, Extra-Adrenal/diagnostic imaging , Paraganglioma, Extra-Adrenal/pathology , Radionuclide Imaging
5.
J R Soc Promot Health ; 119(4): 235-9, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10673844

ABSTRACT

Prevention and treatment of obesity are major clinical problems encountered in the management of Type 2 diabetes mellitus (DM); indeed, up to 90% of such patients are regarded as being overweight. Except for a brief period following diagnosis, when presumably enthusiasm to adopt lifestyle change is at its greatest, weight gain is generally progressive unless severe hyperglycaemia or complications intervene. Even a relatively modest weight loss of 10% can have major benefits in terms not only of reducing the risk of developing DM in the first place, but also in improving metabolic control after the disorder has become established. Behavioural therapy (BT) in combination with hypocaloric diet achieves weight loss in the short-term, but is poorly sustained in the long-term. Exercise has metabolic benefits beyond its rather minimal effects on short-term weight loss in that it may also aid long-term weight control. The difficulties encountered in maintaining lifestyle change do, however, suggest the need for ongoing intervention--perhaps including a regular period on a stricter dietary regimen (800-1000 kcalday-1), possibly a very low calorie diet (VLCD)(< 800 kcalday-1) or even the use of orlistat, a pancreatic lipase inhibitor which reduces the absorption of dietary fat. Realistically, the aim should be for long-term weight stability.


Subject(s)
Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/prevention & control , Obesity/complications , Obesity/prevention & control , Weight Gain , Anti-Obesity Agents/therapeutic use , Behavior Therapy , Diet, Diabetic , Diet, Reducing , Exercise , Humans , Lactones/therapeutic use , Life Style , Orlistat , Weight Loss
6.
Ann Hum Biol ; 24(4): 289-98, 1997.
Article in English | MEDLINE | ID: mdl-9239434

ABSTRACT

This study compares how effectively the ponderal index and the body mass index adjust birthweight for length at different gestations, and derives an improved index suitable for all gestations. The study was a cross-sectional survey, in a London teaching hospital, using a total of 999 neonates of 33 weeks gestation or later. Main outcome measures were the ponderal index (birthweight/length3), body mass index (birthweight/length2), and Benn index (birthweight/length(n)), where the length power n varies with gestation and is estimated by log-log regression. Results showed that up to 39 weeks gestation, the ponderal index is uncorrelated with length and so is a good index of birthweight for length. Past 39 weeks gestation, the ponderal index is negatively correlated with length, while the body mass index is uncorrelated, so that the body mass index is better. Neither index is optimal at all gestations. Deriving the Benn index (birthweight/length(n)) for each week of gestation, choosing n to make the index uncorrelated with length, shows that n falls steadily and very significantly (p < 0.0001) with increasing gestation. This in turn means that predicted birthweight for length depends on gestation: for a neonate 48 cm long, predicted birthweight varies from 2485 g at 34 weeks to 3030 g at 43 weeks, a 20% range. However, for a 54 cm long infant, predicted birthweight is the same at all gestations. A Benn index where the value of n changes linearly with gestation is described. We conclude that the ponderal index is not appropriate for measuring intra-uterine malnutrition, as it fails to adjust for length at all gestations. No other index of birthweight/length(n) with constant n is any better, as different gestations require different indices. Birthweight predicted from an infant's length depends on the infant's gestation. If, as Barker proposes, thinness at birth assessed by birthweight for length is used to predict later health status, more account needs to be taken of the complex relationship between birthweight, length and gestation.


Subject(s)
Birth Weight , Body Height , Body Mass Index , Female , Fetal Diseases/diagnosis , Fetal Growth Retardation/diagnosis , Gestational Age , Humans , Infant, Newborn , Male , Nutrition Disorders/diagnosis , Pregnancy
7.
Br J Obstet Gynaecol ; 98(6): 524-7, 1991 Jun.
Article in English | MEDLINE | ID: mdl-1873240

ABSTRACT

Head circumference/abdominal circumference (HC/AC) ratios of the fetus are accepted as a means of distinguishing different patterns of growth retardation with a high ratio implying malnutrition of the fetus. Ponderal index (birthweight/length3) is used by paediatricians as a measure of neonatal wasting and would therefore be expected to correlate with HC/AC ratios at delivery. Anthropometric data on 999 newborn infants have been collected and analyzed by multiple regression. The results show a poor correlation between ponderal index and HC/AC ratio, worse than that between ponderal index and AC alone. The use of HC/AC ratios antenatally to identify subgroups of intrauterine malnutrition should be abandoned. The prediction of intrauterine malnutrition by weight/length ratios should be investigated further.


Subject(s)
Anthropometry/methods , Fetal Growth Retardation/diagnosis , Birth Weight , Body Height , Cephalometry , Female , Gestational Age , Humans , Infant, Newborn , Male , Pelvimetry , Pregnancy , Regression Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...